ASCO 2013

ASCO 2013

Pazopanib Maintenance Therapy Delays Relapse in Advanced Ovarian Cancer

Maintenance therapy with pazopanib after successful initial chemotherapy for advanced ovarian cancer prolongs time to relapse and PFS compared to placebo, found research presented at ASCO 2013.

Adjuvant Bevacizumab Well-Tolerated in Patients with Melanoma at High Risk of Recurrence

In patients with melaoma at high risk of recurrence, adjuvant bevacizumab is well tolerated and improves the disease-free interval, found research presented at ASCO 2013.

No Increased Cardiac Toxicity with Dual HER2 Blockade Therapy for Breast Cancer

Combined anti-HER2 therapy, with or without chemotherapy, does not increase the risk for cardiac toxicities compared to anti-HER2 monotherapy, found research presented at ASCO 2013.

Chemotherapy Drug Shortages Affect Patient Care, Impact Clinical Trials

A survey found that 83% of U.S. oncologists/hematologists reported a chemo drug shortage in the past 6 months, with 94% stating patient care was affected, according to data presented at ASCO 2013.

ADT Can Be Safely Reduced to 18 Months in Patients with Localized High-Risk Prostate Cancer

In men with localized high-risk prostate cancer, androgen-deprivation therapy can be safely reduced from 36 to 18 months, according to research presented at ASCO 2013.

Statins plus Aspirin Improve Overall Survival in Uterine Malignancies

Women with uterine malignancies who took statins and aspirin had an 84% reduction in mortality, while use of statins alone reduced mortality by 45%, according to data presented at ASCO 2013.

Anti-PD-L1 Agent Induces Durable Responses in Several Advanced Cancer Tumor Types

MPDL3280A produced durable responses in patients with locally advanced or metastatic lung cancer, melanoma, and renal, colorectal, and gastric cancers, some within days of treatment initiation, found research at ASCO 2013.

Nintedanib plus Docetaxel Prolongs PFS in Patients with Metastatic NSCLC

Nintedanib in combination with docetaxel significantly prolonged PFS for patients with metastatic NSCLC progressing after first-line chemotherapy regardless of histology, results from the LUME-Lung 1 trial presented at ASCO 2013 have found.

Number of Breast Cancer Gene Alterations Predicts Everolimus Benefit

The number of genetic alterations in tumors may predict which patients with breast cancer will benefit from adding everolimus to exemestane, found research presented at ASCO 2013.

VeriStrat 'Clinically Useful to Guide Treatment' in Advanced Lung Cancer

VeriStrat test status predicts which patients will see survival benefits from second-line chemotherapy instead of erlotinib therapy for advanced NSCLC, found data presented at ASCO 2013.

Standard-dose RT Superior to High-dose in Patients with Stage III NSCLC Undergoing Chemo

Standard-dose radiation therapy is superior to high-dose RT in terms of OS and local-regional control in patients undergoing chemotherapy for stage III NSCLC, found research presented at ASCO 2013.

Imatinib Rechallenge Prolongs PFS but not Overall Survival in Advanced GIST

Imatinib is prolongs PFS but not OS compared to placebo among patients with imatinib- or sunitinib-refractory advanced GIST, according to data presented at ASCO 2013.

New PI3K-delta Inhibitor Shows Early Promise for High-risk CLL

Idelalisib (GS-1101) is associated with rapid tumor response in some patients diagnosed with relapsed or treatment-resistant CLL, found research presented at ASCO 2013.

Poorer Outcomes Observed for Elderly vs Younger Patients with Metastatic Pancreatic Cancer

Elderly patients with metastatic pancreatic cancer have shorter OS and receive less chemotherapy, fewer agents compared to younger patients, found research presented at ASCO 2013.

Next Generation DNA Sequencing Promising in Identifying Targets for Personalized Treatments

NGS shows promise in identifying solid tumors harboring "actionable" genetic alterations that can be targeted for personalized therapy, according to study results presented at ASCO 2013.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs